Regula Software Now Supports the Latest Standard for Biometric Passport Verification
18.2.2025 14:00:00 CET | Business Wire | Press release
With its latest update, Regula Document Reader SDK, a comprehensive software solution for identity document verification, ensures 100% support for the new ISO/IEC 39794-5 standard regulating the methods of facial data storage and verification in e-passport chips. According to the ICAO guidelines, all document readers and verification systems must be compatible with the new standard by 2026, with passport issuers required to fully adopt the new format by 2030.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218969889/en/
Regula Document Reader SDK correctly extracts and verifies facial data encoded in the e-passport chip under the new ISO/IEC 39794-5 standard. (Graphic: Regula)
The ISO/IEC 39794-5 standard introduces an enhanced framework for facial image data, significantly improving interoperability, processing speed, and recognition accuracy across different identity verification (IDV) systems worldwide. Unlike the previous ISO/IEC 19794-5:2005 standard, which primarily stored a basic facial image, the new format records additional metadata, including detailed facial landmarks, precise eye and hair color, and other biometric attributes.
Why this matters
The richer set of pre-stored reference points eliminates the need for separate face detection and feature extraction during verification. Instead of calculating key facial points from scratch, IDV systems can use the pre-recorded metadata, accelerating processing times and ensuring consistent, high-quality recognition results—regardless of the local algorithm used for comparison. This standardization guarantees that a person’s face in their passport will be consistently and accurately verified across different countries, improving global interoperability.
Apart from that, the ISO/IEC 39794-5 standard implements a flexible framework for future extensions. This means that as new attributes or enhancements are introduced in the future, all systems supporting this standard will remain fully functional without requiring urgent updates—unlike the current situation, where all IDV systems would need to be updated to accommodate new data formats.
Preparing for the transition
Although the current ISO/IEC 19794-5:2005 will remain valid, the industry has started the transition period, and businesses worldwide should be ready to process the new format data before 2026.
Regula’s long-standing expertise in secure RFID chip reading and trustworthy data verification ensured smooth adaptation to the new standard even prior to its coming into force. The company’s participation in the recent testing event in Australia demonstrated its ability to correctly extract, interpret, and verify biometric facial data encoded according to ISO/IEC 39794-5. This means that identity verification systems using Regula’s software are future-proofed against compatibility issues that could arise as countries transition to the new format.
In addition, the new standard will require organizations from banks to border control to update their passport readers with software that fits this standard. Regula's IDV software is compatible with most document readers on the market and can be easily used with any device model. This implies a seamless transition to the new standard without replacing existing hardware, ensuring a cost-effective and hassle-free upgrade.
“The shift to ISO/IEC 39794-5 is a major step forward in improving compatibility and efficiency in biometric verification. With more detailed metadata now embedded in e-passports, identity verification systems can achieve faster processing and more accurate recognition results. Our expertise in RFID chip processing ensures that Regula’s technology is already fully equipped to support this transition, providing organizations with seamless, future-proof solutions that help them stay in line with regulatory changes,” says Ihar Kliashchou, Chief Technology Officer at Regula.
To get additional information about the latest update to Regula Document Reader SDK, read the technical documentation. If you are interested in learning more about how Regula processes RFID chip data, visit the official website.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218969889/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom